The upgrade rate of a site of atypical ductal hyperplasia (ADH) identified on percutaneous biopsy with a concurrent ipsilateral breast cancer is not significantly higher than historical upgrade rates for ADH alone. When considering breast conservation for breast cancer, omitting excision of the site of ADH can be considered when high-risk features are not present, such as individual cell necrosis or ipsilateral DCIS, or if ADH was biopsied using ultrasound guidance.1
Reference
Amin AL, Fan F, Winblad OD, Larson KE, Wagner JL. Ipsilateral and concurrent breast cancer and atypical ductal hyperplasia: does atypia also need surgical excision? Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08896-7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
All authors have no commercial interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Amin, A.L., Fan, F., Winblad, O.D. et al. ASO Visual Abstract: Does Ipsilateral Cancer Increase Atypical Ductal Hyperplasia Upgrade?. Ann Surg Oncol 27 (Suppl 3), 673 (2020). https://doi.org/10.1245/s10434-020-08948-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08948-y